查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197207

脑积水分流器市场-增长、趋势、COVID-19 影响和预测 (2023-2028)

Hydrocephalus Shunts Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，脑积水分流器市场的复合年增长率预计为 8%。

世界面临 COVID-19 的巨大威胁。 据世界卫生组织 (WHO) 称，COVID-19 具有传染性，许多感染该病毒的人会出现轻度至中度呼吸道疾病。 COVID-19的爆发对脑积水分流器市场产生了重大影响。 世界各地的封锁措施减少了公民的流动。 临床研发试验和手术也受到影响，因为非紧急程序被推迟以减轻医疗基础设施的压力。 根据 Neurology Online Journal 发表的一项研究，到 2020 年，COVID-19 可能会在新的神经系统疾病的发展中发挥作用。 新残疾的增加与更高的院内死亡风险和更低的提前出院可能性相关。 在这项研究中，606 名被诊断患有脑部或其他神经相关病症的成年 COVID-19 患者在感染的任何时间都受到密切随访。 结果造成了范围广泛的伤害，从因体内氧气含量低导致的暂时意识模糊到严重情况下的中风和癫痫发作不等。 这些因素可能对研究市场产生积极影响。

市场的增长归因于人口老龄化、大脑和神经系统疾病患病率上升以及先进可编程阀门的日益普及。 神经外科医生倾向于使用最先进的分流器、防虹吸装置和先进的可编程阀门。 防虹吸装置有助于避免对脑脊液的虹吸效应。 脑部疾病的增加增加了对用于治疗脑积水的先进分流器的需求。 例如，根据美国生物化学与分子生物学学会 2021 年 3 月发表的一篇论文，美国每年约有 280 万人遭受创伤性脑损伤 (TBI)，约有 28 万人住院治疗。 每天大约有 50,000 例死亡病例和 155 人死于与 TBI 相关的伤害，这促进了市场的增长。 多家公司将重点放在产品发布、产品批准和扩大其神经外科产品组合上，预计将推动脑积水分流器市场的发展。 然而，与使用脑积水分流器感染相关的问题可能会阻碍市场增长。

脑积水分流术的市场趋势

预计在预测期内脑积水导管将主导市场

导管是脑积水管理的重要组成部分，某些患者群体发生分流感染的风险增加。 导管将脑脊液 (CSF) 从 CSF 过多的区域转移到 CSF 被吸收的身体区域。

近端导管（脑室或腰椎导管）通过其起点处的一系列小孔从脑室或腰椎脊髓囊中排出多余的脑脊液。 远端导管通常留在腹腔内。 然而，它们可以放置在更适合将脑脊液排入血液的地方，例如心臟或胸腔（肺）。

这些设备在解决生物相容性、感染和污染问题方面的技术进步预计将促进这一细分市场的增长。 例如，一些分流导管浸有抗生素以降低术后感染的发生率，例如CODMAN BACTISEAL导管和Medtronic Ares导管。 Ares 抗生素浸渍导管可有效抵抗细菌定植。

此外，目前的研究主要集中在脑积水导管的潜在重新设计上，这可能会促进这一细分市场的增长。 例如，2020 年，麻省理工学院的研究人员在英国皇家学会界面杂誌上发表了一篇论文，提出并验证了脑积水导管的新设计原则。 该设计试图克服这些设备的核心挑战，即脑积水导管的周期性堵塞。 这种新的设计原则可以防止脑分流术中的导管失效。

这些产品作为治疗脑积水和其他脑部疾病的潜在产品而受到广泛关注。 因此，这些因素可能会在预测期内显着推动该行业的增长。

预计在预测期内北美将占据很大的市场份额

由于脑积水患者数量的增加以及对神经系统疾病管理的日益关注，预计北美将占据很大的市场份额。 据脑积水协会估计，2019 年美国将有 100 万人患有脑积水，每 1000 名婴儿中就有 1 人患有脑积水，这促使脑积水分流术的采用和该地区的增长将得到促进。

在美国市场增长的背景下，老年人口增加，脑部和神经系统疾病患病率增加，先进可编程阀门的采用率增加。 受此类疾病影响的人口比例很高，预计将推动对这些产品的需求。 多个参与者对产品发布、批准和扩展其神经外科产品组合的关注将推动美国的脑积水分流器市场。 例如，2020 年 Aesculap Inc. 与 Christoph Miethke GmbH & Co. 合作推出了 M.blue 分流器。 KG推出最新一代脑积水瓣膜技术“M.blue Valve”。 其独特的重力技术集成到一个固定的压差装置和一个阀门中，从而实现了一种简单的、与位置无关的解决方案。

此外，不断上涨的医疗成本和完善的医疗基础设施极大地推动了该地区市场的增长。

脑积水分流器市场竞争对手分析

脑积水分流术市场竞争适中，由几家大型企业组成。 从市场份额的角度来看，几家主要参与者目前主导着市场，其中包括 Christoph Miethke GmbH & Co.KG、Medtronic PLC、Sophysa、Tokibo、Spiegelberg GmbH & .Braun Melsungen AG、Integra LifeSciences Corporation、强生。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 脑部和神经系统疾病的患病率上升
    • 老年人口增加
    • 更多地采用先进的可编程阀门
  • 市场製约因素
    • 分流功能障碍、分流感染
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品类型
    • 脑积水阀
      • 压力控制阀
      • 固定压力阀
    • 脑积水导管
  • 按年龄段
    • 儿科
    • 成人
  • 最终用户
    • 医院
    • 门诊手术中心
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东
    • 南美洲

第六章竞争格局

  • 公司简介
    • Christoph Miethke GmbH & Co. KG
    • Medtronic PLC
    • Sophysa
    • Tokibo Co. Ltd
    • Spiegelberg GmbH & Co. KG
    • B. Braun Melsungen AG
    • Integra LifeSciences Corporation
    • Johnson & Johnson

第7章 市场机会今后动向

简介目录
Product Code: 68434

The hydrocephalus shunts market is expected to register a CAGR of 8% during the forecast period.

The world has been facing the huge threat of COVID-19. As per the World Health Organization (WHO), COVID-19 is infectious, and most people infected by the virus experience mild to moderate respiratory illness. The COVID-19 outbreak had a significant impact on the hydrocephalus shunts market. The lockdown measures across the world resulted in decreased public mobility. They also impacted the clinical R&D studies and surgeries, as the procedures that were non-immediate were postponed to decrease the burden on healthcare infrastructure. As per the study published by the Neurology Online Journal, in 2020, COVID-19 could potentially be responsible for the patients developing new neurological disorders. The increase in new disorders resulted in a higher risk of in-hospital mortality and decreased likelihood of being discharged sooner. The study closely monitored 606 adult COVID-19 patients diagnosed with brain or other nerve-related medical conditions at any point of their infection. The injuries incurred ranged from temporary confusion due to low body-oxygen levels to stroke and seizures in serious cases. Such factors may positively influence the market studied.

The market's growth is attributed to the growing geriatric population, a rising prevalence of brain and neurological disorders, and the increasing adoption of advanced programmable valves. Neurosurgeons are inclining toward the latest technology shunts, antisiphon devices, and advanced programmable valves. Antisiphone devices help in avoiding siphon effects over cerebrospinal fluid. The increasing prevalence of brain disorders is leading to high demand for advanced shunts for treating hydrocephalus. For instance, according to an article published by the American Society for Biochemistry and Molecular Biology in March 2021, in the United States, about 2.8 million people sustain a traumatic brain injury (TBI) every year, with some 280,000 resulting in hospitalizations. Approximately 50,000 are fatal cases causing 155 deaths every day from TBI-related injuries, which are contributing to the market's growth. Product launches, product approvals, and an increased focus by several players on expanding product portfolios in neurosurgery are anticipated to boost the hydrocephalus shunts market. However, issues regarding the infections caused using hydrocephalus shunts may hamper the market's growth.

Hydrocephalus Shunts Market Trends

Hydrocephalus Catheters are Expected to Dominate the Market During the Forecast Period

Catheters are an important part of managing hydrocephalus, and certain patient populations are at greater risk of developing shunt infections. Catheters divert cerebrospinal fluid (CSF) from the site with an excess volume of CSF to a location within the body where the CSF will be absorbed.

The proximal catheter (ventricular or lumbar catheter) drains excess CSF from the ventricles or the lumbar spinal sac through rows of small holes at its origin. Distal catheters are typically placed in the abdominal cavity. However, they can also be placed in the heart, pleural cavity (lungs), and other suitable locations where CSF is drained into the bloodstream.

Technological advancements in these devices to combat the issues of biocompatibility, infection, and fouling are expected to contribute to the segment's growth. For instance, some shunt catheter is impregnated with antibiotics to reduce the incidence of infection during the post-operative period, such as the CODMAN BACTISEAL catheter and the Medtronic Ares catheter. The Ares antibiotic-impregnated catheters help reduce bacterial colonization.

In addition, current research focuses on the potential redesign of the hydrocephalus catheters, which may boost the segment's growth. For instance, in 2020, MIT researchers published a paper in the Journal of the Royal Society Interface, which proposes and validates a new design principle for hydrocephalus catheters. The design seeks to overcome a central challenge of these devices where they regularly become clogged. The new design principle could prevent catheter failure in brain shunts.

These products have attracted a significant amount of attention due to their potential prospects in the treatment of hydrocephalus and other brain disorders. Thus, such factors may boost the segment's growth significantly over the forecast period.

North America is Expected to Hold a Significant Share in the Market During the Forecast Period

North America is expected to hold a significant market share due to the rise in the number of patients with hydrocephalus and the growing emphasis on the management of neurological disorders. As per the Hydrocephalus Association, in 2019, an estimated 1 million people in the United States were affected by hydrocephalus, and 1 in every 1,000 babies had hydrocephalus, thus leading to the adoption of hydrocephalus shunts and promoting the growth in this region.

The growth of the US market is attributed to the rising geriatric population, rising prevalence of brain and neurological disorders, and increasing adoption of advanced programmable valves. Such a large population base suffering from the disease is expected to drive the demand for these products. Product launches, approval, and increased focus by several players on their expanding product portfolios in neurosurgery will propel the US hydrocephalus shunts market. For instance, in 2020, Aesculap Inc., in partnership with Christoph Miethke GmbH & Co. KG, launched the M.blue Valve, the latest generation of hydrocephalus valve technology. Its unique gravitational technology is integrated with a fixed differential pressure unit in one valve, allowing for a simple, position-dependent solution.

Furthermore, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are fueling the regional market's growth to a large extent.

Hydrocephalus Shunts Market Competitor Analysis

The hydrocephalus shunts market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market, including Christoph Miethke GmbH & Co. KG, Medtronic PLC, Sophysa, Tokibo Co. Ltd, Spiegelberg GmbH & Co. KG, B. Braun Melsungen AG, Integra LifeSciences Corporation, and Johnson & Johnson.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Brain and Neurological Disorder
    • 4.2.2 Increase in Geriatric Population
    • 4.2.3 Increasing Adoption of Advanced Programmable Valves
  • 4.3 Market Restraints
    • 4.3.1 Shunt Malfunction and Shunt Infection
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Hydrocephalus Valves
      • 5.1.1.1 Adjustable Pressure Valves
      • 5.1.1.2 Fix Pressure Valves
    • 5.1.2 Hydrocephalus Catheters
  • 5.2 By Age Group
    • 5.2.1 Pediatric
    • 5.2.2 Adult
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.2 Europe
    • 5.4.3 Asia-Pacific
    • 5.4.4 Middle-East
    • 5.4.5 South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Christoph Miethke GmbH & Co. KG
    • 6.1.2 Medtronic PLC
    • 6.1.3 Sophysa
    • 6.1.4 Tokibo Co. Ltd
    • 6.1.5 Spiegelberg GmbH & Co. KG
    • 6.1.6 B. Braun Melsungen AG
    • 6.1.7 Integra LifeSciences Corporation
    • 6.1.8 Johnson & Johnson

7 MARKET OPPORTUNITIES AND FUTURE TRENDS